“Chronic Lower Back Pain Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chronic Lower Back Pain Market.
The Chronic Lower Back Pain Pipeline report embraces in-depth commercial, regulatory, and Chronic Lower Back Pain clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Chronic Lower Back Pain drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Chronic Lower Back Pain Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Chronic Lower Back Pain treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Chronic Lower Back Pain therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Chronic Lower Back Pain companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Chronic Lower Back Pain drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chronic Lower Back Pain therapeutic market.
Chronic Lower Back Pain Therapeutics Landscape
The majority of low back pain is caused by a mechanical etiology, which includes a degenerative disc or joint disease, vertebral fracture, and deformities and occurs in up to 80–90% of patients, while neurogenic, inflammatory, and other less common causes make up the remainder of etiologies. The pharmacologic agents first selected must be focused on the underlying etiology. However, as the pain progresses to a chronic state, a broader approach typically must be taken due to the decreased efficacy of the targeted treatment.
However, if the cause of low back pain is inflammatory, targeted therapy includes treatment with anti‐inflammatory agents. This refers to the early use of non-steroidal anti‐inflammatories (NSAIDs) and treatment with corticosteroids or disease‐modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis or ankylosing spondylitis. Additionally, these disease states have a higher incidence of neuropathic pain and thus may require adjuvant medications that target this specific pain type. Some patients with mechanical low back pain also have increased pain due to spasticity and may benefit from treatment with antispasmodics.
In addition to pharmacologic treatments, non-pharmacologic treatments including topical heat for acute pain or cognitive behavioral therapy, exercise therapy, spinal manipulation and interdisciplinary rehabilitation for subacute or chronic pain are necessary.
There are approx. 10+ key companies developing therapies for Chronic Lower Back Pain. Currently, Mesoblast is leading the therapeutics market with its Chronic Lower Back Pain drug candidates in the most advanced stage of clinical development.
Chronic Lower Back Pain Companies Actively Working in the Therapeutic Market Include:
-
Mesoblast
-
Eli Lilly and Company
-
Persica Pharmaceuticals
-
CHABiotech
-
Allodynic Therapeutics
-
Stayble Therapeutics
-
Xgene Pharmaceutical
-
Imbrium Therapeutics
-
Camurus
And Many Others
Emerging and Marketed Chronic Lower Back Pain Drugs Covered in the Report Include:
-
MPC-06-ID: Mesoblast
-
PP353: Persica Pharmaceuticals
-
Brixadi (CAM2038/buprenorphine injection depot): Camurus/Braeburn
-
Semdexa (SP-102, dexamethasone sodium phosphate): Scilex Holding
-
AMG0103: AnGes MG, Inc.
And Many Others
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Chronic Lower Back Pain Companies Working in the Market @
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight
Analysis of Emerging Chronic Lower Back Pain Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Chronic Lower Back Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the Chronic Lower Back Pain Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Chronic Lower Back Pain Treatment Patterns
4. Chronic Lower Back Pain – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Chronic Lower Back Pain Late Stage Products (Phase-III)
7. Chronic Lower Back Pain Mid-Stage Products (Phase-II)
8. Chronic Lower Back Pain Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Lower Back Pain Discontinued Products
13. Chronic Lower Back Pain Product Profiles
14. Major Chronic Lower Back Pain Companies in the Market
15. Key Products in the Chronic Lower Back Pain Therapeutics Segment
16. Dormant and Discontinued Products
17. Chronic Lower Back Pain Unmet Needs
18. Chronic Lower Back Pain Future Perspectives
19. Chronic Lower Back Pain Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Cerebral Palsy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cerebral Palsy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Cerebral Palsy market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research